Loading stock data…
$1.05+0.06 (+5.56%)
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
IN8bio, Inc. in the Healthcare sector is trading at $1.05 with a market capitalization of $11M. Wall Street consensus targets $7.00 (3 analysts), implying a +566.7% move over the next 12 months. The stock is currently near its 52-week low of $0.88, remaining 29.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.93M↑ | -$5.27M↓ | -$5.03M↓ | -$3.97M↑ | -$5.20M |
| Net Income | -$4.78M↑ | -$5.09M↓ | -$4.94M↓ | -$3.85M↑ | -$5.09M |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include I...